In CD4+ and CD8+ T cells and leukemic cells, TIM3 overexpression may lead to poor response and relapse in patients; therefore, TIM3 inhibitors are currently being investigated as potential AML treatments. This evidence concerns the gene CD8A and acute myeloid leukemia.